Quote:

---

I have never seen a company with this many shares jump from .50 cents to $10.00 it is extremely unlikely.

---

I've seen others make the same statements about past BOs and the % between pps and purchase price. But I think Cytodyn is different.

Our value is obviously immense but the pps has been artificially supressed for a long, long time. Is the inherent value less now at .50 than it was when we were at $10? No, the inherent value has only gone up. More data, more indications, etc.

Okay, let's accept your premise and say we're only worth $5 now, because .50 to $5 is a reasonable jump in a BO scenario, right? But what if MMs took it to 5c tomorrow? Does that mean Leronlimab is then only worth 50c per share?

The other argument is that we have zero value because we don't have an approval yet. Does that mean a 17 year-old basketball player has zero *inherent* value until they're drafted? What if your team was somehow allowed by the NBA to make a deal with the next LeBron *before* the draft? Would you be justified in only offering him $10k per year salary? After all, he's not "approved" yet by the legitimacy of the draft.

Ultimately, Leronlimab (and Cytodyn) is worth a multiple of whatever its value *will* be, and there's enough evidence to all but prove it will be worth many billions. We've all seen the list of indications and we can all do the math (ok, I'll admit I let you guys do the math while I sit back and drink IPAs).

So there's no need to base (or doubt) a potential BO number on whatever % increase in value some podunk biotech (with a single drug that has a ton of side effects) may have enjoyed in the past.

Big Pharma often buys companies speculating on future growth and earnings. They take risks. They KNOW Leronlimab could net tens of billions in revenue every year.

My preference remains a partnership and steady price rise to astronomical levels over the next few years, but I won't rule out a BO at a "fair" price.